Esperion completes $100M convertible note issuance and exchange of 2025 notes

Esperion Therapeutics, Inc.

Issued $100M aggregate principal of 5.75% Convertible Senior Subordinated Notes due June 15, 2030.
Exchanged ~$210.1M of existing 4.00% 2025 Notes for ~$57.5M new notes plus ~$153.4M cash.
Sold ~$42.5M of new notes for cash; net proceeds for general corporate purposes.
Initial conversion rate 326.7974 shares per $1,000 principal, conversion price ~$3.06 per share.
New notes are senior unsecured, redeemable after Dec 20, 2027 under certain conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.